Karyopharm Therapeutics Target of Unusually High Options Trading (KPTI)

Karyopharm Therapeutics Inc (NASDAQ:KPTI) was the target of unusually large options trading on Thursday. Traders acquired 2,626 call options on the company. This is an increase of approximately 3,142% compared to the typical daily volume of 81 call options.

Shares of KPTI stock opened at $8.93 on Friday. The firm has a market cap of $546.98 million, a P/E ratio of -3.18 and a beta of 3.42. Karyopharm Therapeutics has a 12 month low of $8.01 and a 12 month high of $21.71.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, November 8th. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.09. Karyopharm Therapeutics had a negative net margin of 502.90% and a negative return on equity of 104.50%. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $1.21 million. Analysts expect that Karyopharm Therapeutics will post -2.97 EPS for the current year.

A number of equities analysts recently commented on KPTI shares. BidaskClub downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. ValuEngine downgraded shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Thursday, January 10th. Wedbush upgraded shares of Karyopharm Therapeutics from a “neutral” rating to an “outperform” rating and set a $19.00 target price for the company in a research note on Friday, November 9th. Finally, Bank of America upgraded shares of Karyopharm Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $21.90.

In other news, insider Sharon Shacham sold 12,500 shares of the company’s stock in a transaction on Friday, December 7th. The stock was sold at an average price of $10.11, for a total transaction of $126,375.00. Following the sale, the insider now owns 726,010 shares of the company’s stock, valued at $7,339,961.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Kauffman sold 9,600 shares of the company’s stock in a transaction on Monday, November 26th. The stock was sold at an average price of $11.00, for a total value of $105,600.00. Following the sale, the chief executive officer now directly owns 521,743 shares in the company, valued at approximately $5,739,173. The disclosure for this sale can be found here. Insiders have sold 35,000 shares of company stock worth $364,306 in the last ninety days. Corporate insiders own 13.26% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. IFP Advisors Inc boosted its stake in Karyopharm Therapeutics by 197.4% in the fourth quarter. IFP Advisors Inc now owns 5,650 shares of the company’s stock valued at $52,000 after acquiring an additional 3,750 shares in the last quarter. Virtu Financial LLC acquired a new position in Karyopharm Therapeutics in the third quarter valued at $195,000. Verition Fund Management LLC acquired a new position in Karyopharm Therapeutics in the third quarter valued at $242,000. Fox Run Management L.L.C. acquired a new position in Karyopharm Therapeutics in the third quarter valued at $266,000. Finally, Voya Investment Management LLC boosted its stake in Karyopharm Therapeutics by 24.3% in the second quarter. Voya Investment Management LLC now owns 18,661 shares of the company’s stock valued at $317,000 after acquiring an additional 3,653 shares in the last quarter. Institutional investors own 72.65% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2019/02/08/karyopharm-therapeutics-target-of-unusually-high-options-trading-kpti.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Read More: Options Trading – What is a Straddle?

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply